North China Pharmaceutical Company.Ltd (SHA:600812)
China
· Delayed Price · Currency is CNY 5.79
-0.22 (-3.66%)
Mar 10, 2026, 3:00 PM CST
SHA:600812 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 9,722 | 9,798 | 10,070 | 10,449 | 10,304 | 11,430 | Upgrade
|
| Other Revenue | 71.76 | 71.76 | 50.32 | 51.19 | 80.2 | 62.02 | Upgrade
|
| Revenue | 9,794 | 9,870 | 10,120 | 10,500 | 10,385 | 11,493 | Upgrade
|
| Revenue Growth (YoY) | 0.91% | -2.48% | -3.62% | 1.11% | -9.64% | 0.31% | Upgrade
|
| Cost of Revenue | 6,755 | 6,732 | 6,907 | 7,063 | 6,691 | 7,405 | Upgrade
|
| Gross Profit | 3,039 | 3,138 | 3,213 | 3,437 | 3,694 | 4,087 | Upgrade
|
| Selling, General & Admin | 1,908 | 2,010 | 2,268 | 2,424 | 2,796 | 3,179 | Upgrade
|
| Research & Development | 338.29 | 336.15 | 294.2 | 215.17 | 151.93 | 135.69 | Upgrade
|
| Other Operating Expenses | 94.22 | 90.82 | 104.23 | 117.57 | 123.33 | 137.44 | Upgrade
|
| Operating Expenses | 2,396 | 2,465 | 2,677 | 2,802 | 3,094 | 3,489 | Upgrade
|
| Operating Income | 642.82 | 672.93 | 536.44 | 634.8 | 600.11 | 597.87 | Upgrade
|
| Interest Expense | -389.27 | -458.7 | -501.9 | -599.39 | -642.69 | -572.02 | Upgrade
|
| Interest & Investment Income | 78.29 | 71.42 | 74.52 | 84.17 | 126.62 | 66 | Upgrade
|
| Currency Exchange Gain (Loss) | 17.57 | 17.57 | 11.49 | 23.31 | -8.32 | -29.94 | Upgrade
|
| Other Non Operating Income (Expenses) | -8.02 | -5.15 | -11.35 | -748.96 | -13.91 | -15.35 | Upgrade
|
| EBT Excluding Unusual Items | 341.4 | 298.08 | 109.2 | -606.07 | 61.82 | 46.55 | Upgrade
|
| Impairment of Goodwill | -3.34 | -3.34 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.63 | 0.31 | 0.76 | 0.21 | 3.4 | 1.07 | Upgrade
|
| Asset Writedown | 19.03 | -1.26 | -0.05 | - | - | - | Upgrade
|
| Legal Settlements | -0.5 | -0.5 | -0.49 | -0.78 | -1.14 | -1.64 | Upgrade
|
| Other Unusual Items | 16.86 | 16.55 | 49.12 | 41.56 | 70.84 | 140.7 | Upgrade
|
| Pretax Income | 374.07 | 309.83 | 158.54 | -565.07 | 134.91 | 186.68 | Upgrade
|
| Income Tax Expense | 94.01 | 94.87 | 109.15 | 113.71 | 99.52 | 82.2 | Upgrade
|
| Earnings From Continuing Operations | 280.06 | 214.97 | 49.39 | -678.78 | 35.38 | 104.48 | Upgrade
|
| Minority Interest in Earnings | -97.03 | -87.97 | -44.5 | -10.45 | -16.65 | -7.15 | Upgrade
|
| Net Income | 183.03 | 126.99 | 4.89 | -689.23 | 18.73 | 97.32 | Upgrade
|
| Net Income to Common | 183.03 | 126.99 | 4.89 | -689.23 | 18.73 | 97.32 | Upgrade
|
| Net Income Growth | 130.57% | 2496.79% | - | - | -80.76% | -43.46% | Upgrade
|
| Shares Outstanding (Basic) | 1,727 | 1,716 | 1,630 | 1,715 | 1,702 | 1,622 | Upgrade
|
| Shares Outstanding (Diluted) | 1,727 | 1,716 | 1,630 | 1,715 | 1,702 | 1,622 | Upgrade
|
| Shares Change (YoY) | 7.99% | 5.27% | -4.92% | 0.70% | 4.96% | -0.12% | Upgrade
|
| EPS (Basic) | 0.11 | 0.07 | 0.00 | -0.40 | 0.01 | 0.06 | Upgrade
|
| EPS (Diluted) | 0.11 | 0.07 | 0.00 | -0.40 | 0.01 | 0.06 | Upgrade
|
| EPS Growth | 113.52% | 2366.67% | - | - | -81.67% | -43.40% | Upgrade
|
| Free Cash Flow | 150.27 | 445.35 | 401.23 | 454.81 | 502.75 | -254.68 | Upgrade
|
| Free Cash Flow Per Share | 0.09 | 0.26 | 0.25 | 0.27 | 0.29 | -0.16 | Upgrade
|
| Dividend Per Share | 0.030 | 0.030 | 0.010 | - | 0.060 | 0.030 | Upgrade
|
| Dividend Growth | 200.00% | 200.00% | - | - | 100.00% | - | Upgrade
|
| Gross Margin | 31.03% | 31.79% | 31.75% | 32.73% | 35.57% | 35.56% | Upgrade
|
| Operating Margin | 6.56% | 6.82% | 5.30% | 6.05% | 5.78% | 5.20% | Upgrade
|
| Profit Margin | 1.87% | 1.29% | 0.05% | -6.56% | 0.18% | 0.85% | Upgrade
|
| Free Cash Flow Margin | 1.53% | 4.51% | 3.96% | 4.33% | 4.84% | -2.22% | Upgrade
|
| EBITDA | 1,468 | 1,461 | 1,275 | 1,347 | 1,224 | 1,218 | Upgrade
|
| EBITDA Margin | 14.99% | 14.81% | 12.60% | 12.83% | 11.79% | 10.60% | Upgrade
|
| D&A For EBITDA | 825.65 | 788.52 | 739.01 | 712 | 624 | 620.12 | Upgrade
|
| EBIT | 642.82 | 672.93 | 536.44 | 634.8 | 600.11 | 597.87 | Upgrade
|
| EBIT Margin | 6.56% | 6.82% | 5.30% | 6.05% | 5.78% | 5.20% | Upgrade
|
| Effective Tax Rate | 25.13% | 30.62% | 68.85% | - | 73.77% | 44.03% | Upgrade
|
| Revenue as Reported | 9,794 | 9,870 | 10,120 | 10,500 | 10,385 | 11,493 | Upgrade
|
| Advertising Expenses | - | 119.86 | 133.01 | 127.89 | 185.19 | 203.55 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.